🧬 D-SOLVE lecture via MS Teams: Hepatitis D in Mongolia – Screening Study among Mongol Migrants in Sweden 👤 Speakers from Karolinska/Sweden & Mongolia 🗓️ Tue, 23 Sept | 🕐 12:45–13:30 CET 🔗 bit.ly/46oxjnH 🔑 ID: 368 532 223 585 | PW: dq64Nb9t #DSOLVE #HepatitisD #PublicHealth

🧬 Join the HBV Community Forum & Int. HBV Meeting in Berlin (Sept 8–12), on-site or online! 🎤 Science meets community – Hepatitis B & D! D-SOLVE’s Heiner Wedemeyer & Helenie Kefalakes will be there. 👉 www.hbvmeeting.org #HBVForum2025 #HepatitisB #HepatitisD

🚀 Exciting News! 🎥 New #HDV-Awareness campaign video by Prof. Percy Knolle (#TUM) on “How does the liver work?” explaining its unique role in the body. #D-SOLVE #LiverSky #HaDEA #EUHealth, @ec.europa.eu.Watch now: youtu.be/jB5lolw737k

📢 EASL Congress: E. Degasperi from our #D-SOLVE Consortium presents results from a large real-life cohort on clinical outcomes of chronic hepatitis D patients. Rates of cirrhosis & liver-related events were lower than expected. ALT, age & HDV RNA were key determinants. #EASL2025 #HepatitisResearch

Significant findings for our #D-SOLVE project: Scientists from #TWINCORE developed a stem cell-based model for the #HepatitisD virus, revealing the transcription factor IRF1 as a target for new treatments, also in association with Hepcludex. More info: twincore.de/news/better-...

🎬 Just Released! 🌍 Dive into our latest #HDV-Awareness - campaign video featuring Dr. Lisa Sandmann & Dr. Helenie Kefalakes (both #HannoverMedicalSchool & #D-SOLVE). Discover the "Standard of Treatment in Germany and Worldwide". Watch now! youtu.be/d7dV2G6tMXA #HepatitisD #LiverHealth

Really interesting work from our collaborators! Looking forward to have this applied to our project @ciim-hannover.bsky.social

📢 New Video! Join Prof. Wedemeyer (Hannover Medical School, #D-SOLVE) as he discusses the symptoms & consequences of untreated #HepatitisD. This video is part of our #Awareness campaign, highlighting the importance of early detection and treatment. Watch now and stay informed! youtu.be/BLnRhVehOlE

Researchers from Hannover Medical School (MHH) identified a marker on NK cells showing how Bulevirtid alleviates liver inflammation in Hepatitis D. Bulevirtid blocks viral entry and reduces inflammation, even with high viral load, by activating the immune marker TIGIT. More info: bit.ly/40VPqi3.

Welcome to the official Bluesky channel of the D‑SOLVE Consortium. We look forward to engaging with the scientific community and stakeholders committed to improving liver health worldwide. Stay tuned for updates and also check our website (www.d-solve-consortium.eu) for more information.